Aquestive Therapeutics, Inc. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
Aquestive Therapeutics, Inc. (AQST) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $70.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2026-08-11
- Aquestive Therapeutics, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-12-31 was $60.00K, a 62.16% increase year-over-year.
- Aquestive Therapeutics, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-09-30 was $0.00.
- Aquestive Therapeutics, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-12-31 was $37.00K, a 362.50% increase year-over-year.
- Aquestive Therapeutics, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-09-30 was $0.00.
- Aquestive Therapeutics, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2025 was $110.00K, a 64.18% increase from fiscal 2024.
- Aquestive Therapeutics, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2024 was $67.00K, a 71.79% increase from fiscal 2023.
- Aquestive Therapeutics, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2023 was $39.00K, a 14.71% increase from fiscal 2022.
- Aquestive Therapeutics, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2022 was $34.00K, a 78.48% decline from fiscal 2021.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $70.00K 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $60.00K derived: sum of 2 quarters · filed 2026-03-04 | $110.00K 10-K · filed 2026-03-04 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $50.00K 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $50.00K 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $37.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $37.00K derived: sum of 2 quarters · filed 2026-03-04 | $67.00K 10-K · filed 2026-03-04 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $30.00K 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $30.00K 10-Q · filed 2025-08-11 | |||
| 2023-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $8.00K derived: sum of 2 quarters · filed 2025-03-05 | $39.00K 10-K · filed 2025-03-05 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $31.00K 10-Q · filed 2024-11-04 | ||
| 2023-06-30 | $31.00K 10-Q · filed 2024-08-06 | |||
| 2022-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $19.00K derived: sum of 2 quarters · filed 2024-03-05 | $34.00K 10-K · filed 2024-03-05 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $15.00K 10-Q · filed 2023-11-06 | ||
| 2022-06-30 | $15.00K 10-Q · filed 2023-08-07 | |||
| 2021-12-31 | $82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $82.00K derived: sum of 2 quarters · filed 2023-03-31 | $158.00K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $76.00K 10-Q · filed 2022-11-01 | ||
| 2021-06-30 | $76.00K 10-Q · filed 2022-08-02 | |||
| 2020-12-31 | -$62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | -$62.00K derived: sum of 2 quarters · filed 2022-03-08 | $0.00 10-K · filed 2022-03-08 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $62.00K 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | $62.00K 10-Q · filed 2021-08-03 | |||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $112.00K 10-Q · filed 2020-11-04 | ||
| 2019-06-30 | $112.00K 10-Q · filed 2020-08-04 | |||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $0.00 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |